login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

CONNECT II clinical trial completes enrolment


Wednesday, 13 Jun 2012 09:43
Ocelot
Ocelot

Avinger has announced that it has successfully completed enrolment in its CONNECT II global clinical trial. A study focused on treatment of peripheral artery disease. CONNECT II is a prospective, multicentre, non-randomised global clinical study that evaluated 100 peripheral artery disease patients with femoropopliteal chronic total occlusion lesions at 15 hospital and clinic sites, including two in the European Union.


As part of the trial, an independent group of physicians are reviewing the angiographic results to determine Ocelot’s safety and efficacy. According to Avinger (manufacturer of this device), it is the first-ever interventional chronic total occlusion (CTO) crossing catheter to use real-time intravascular imaging technology called optical coherence tomography, or OCT. It allows physicians to cross, see and navigate inside totally blocked arteries in the legs of patients suffering from peripheral artery disease.

“We are pleased to reach this significant milestone ahead of schedule and already see promising preliminary data collected,” said John B Simpson, CEO and founder, Avinger. “We appreciate the patient participation and dedicated efforts of our employees, physician investigators and their research staff. Together, we are now one step closer to bringing the Ocelot technology to patients who need it most.”


The company will present CONNECT II aggregate results at the VIVA conference (Las Vegas, USA, 9–12 October 2012), file a 510K with the FDA later this summer, and expects to receive 510K clearance in late 2012. In order to ensure Ocelot is available for use at US CONNECT II sites during the 510K review period, Avinger has also requested FDA approval of an additional 125 patients to be enrolled and treated in a continued access cohort.


“I believe the results from this trial will have a major impact on how physicians treat patients with severe peripheral artery disease. We are pleased that a request for continued access has been submitted. It means the Heart Hospital may be able to continue treating patients with Ocelot in order to quickly improve their mobility and return to a healthier quality of life,” said Matthew Selmon, Heart Hospital Austin, Texas and co-principal investigator for the trial.


“This is the first-ever interventional device that allows us to drill through the totally blocked arteries in the legs while using an integrated camera to see it from the inside,” said Arne Schwindt, St Franziskus Hospital, Muenster, Germany and co-principal investigator in the trial. “This is a major advance for patients suffering from peripheral artery disease, and holds the potential to postpone or entirely avoid surgical bypasses and amputations.”


Ocelot received CE mark in 2011.




Add New Comment

Most popular


First implant completed in thoracoabdominal aortic aneurysm clinical study
Wednesday, 13 Jan 2016
The first US implant of the Gore Excluder thoracoabdominal branch endoprosthesis has taken place during a clinical study of the treatment of aortic aneurysms involving the visceral branch vessels. First implant completed in thoracoabdominal aortic aneurysm clinical study

Systematic review of registry data suggests stroke or death rate after carotid stenting “significantly higher” than after endarterectomy
Monday, 18 Jan 2016
The review, published in the January 2016 issue of the European Journal of Vascular and Endovascular Surgery (EJVES), further concludes that stroke/death rates after carotid stenting often exceed ... Systematic review of registry data suggests stroke or death rate after carotid stenting “significantly higher” than after endarterectomy

Medtronic launches OsteoCool radiofrequency ablation system in the US
Wednesday, 13 Jan 2016
The OsteoCool radiofrequency ablation system is designed to treat patients with painful spinal metastases. The system has been granted US Food and Drug Administration (FDA) 510(k) marketing clearance. Medtronic launches OsteoCool radiofrequency ablation system in the US

Features


Interventional radiology in trauma management
Friday, 05 Feb 2016
The role of interventional radiology in the management of severely traumatised patients began three to four decades ago with the embolization of the internal iliac arteries for massive pelvic ... Interventional radiology in trauma management

Microvascular plugs investigated in embolization of pulmonary arteriovenous malformations
Monday, 30 Nov 2015
Miles Conrad, University of California San Francisco (UCSF), Interventional Radiology section and co-director of the UCSF HHT Centre of Excellence, spoke to Interventional News about a new device ... Microvascular plugs investigated in embolization of pulmonary arteriovenous malformations

Profiles


Gabriel Bartal
Thursday, 26 Nov 2015
“In the early days, I used to have to cut a 7F plastic tube, make side holes, send it off for ... Gabriel Bartal

Lindsay Machan
Thursday, 28 May 2015
“Focusing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions